Padsevonil

Summary

Padsevonil (CHEMBL4297521) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including focal epilepsy and epilepsy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 14
• Chemistry: 432.8 Da · C14H14ClF5N4O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297521
Name	Padsevonil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	52911611
Molecular formula	C14H14ClF5N4O2S
Molecular weight	432.8
InChIKey	DCXFIOLWWRXEQH-SSDOTTSWSA-N

SMILES: COCC1=NN2C(=C(N=C2S1)C(F)(F)F)CN3C[C@H](CC3=O)CC(F)(F)Cl

IUPAC name: (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one

Also known as: Padsevonil, UCB-0942, Ucb0942, UCB0942, PADSEVONIL

Patent coverage: 9 distinct patent families (22 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
focal epilepsy	2	MONDO:0005384	EFO:0004263
epilepsy	1	MONDO:0005027	EFO:0000474
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE1	9
PHASE2	4
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03739840	PHASE3	TERMINATED	A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
NCT02495844	PHASE2	COMPLETED	A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT02625090	PHASE2	TERMINATED	An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
NCT03370120	PHASE2	TERMINATED	Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
NCT03373383	PHASE2	COMPLETED	Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
NCT03168984	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects
NCT03480243	PHASE1	COMPLETED	Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil
NCT03695094	PHASE1	COMPLETED	A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil
NCT04013191	PHASE1	COMPLETED	A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants
NCT04039919	PHASE1	TERMINATED	A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol
NCT04075409	PHASE1	COMPLETED	A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants
NCT04126343	PHASE1	TERMINATED	A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants
NCT04131517	PHASE1	TERMINATED	A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants
NCT04136444	PHASE1	TERMINATED	A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).